Patients with chronic renal failure treated by longterm intermittent haemodialysis may develop a modified form of renal osteodystrophy (Ellis and Peart, 1971a) , characterised by osteomalacia in the presence of minimal or no osteitis fibrosa (Ellis et al., 1977) . This form of dialysis osteomalacia does not improve after treatment with 1,25 dihydroxy vitamin D3 (1,25(OH)2D3) or with la hydroxy vitamin D3 (1aOHD3) (Pierides et al., 1976; Ellis et al., 1977) , and deficiency of 1,25(OH)2D3 is not its sole cause. Recently there has been speculation concerning the role of aluminium intoxication in the production of dialysis osteomalacia and dialysis dementia (Alfrey et al., 1976; Platts et al., 1977; Elliott et al., 1978; McDermott et al., 1978; Ward et al., 1978) . The main sources of aluminium are its salts in the dialysate water and aluminium hydroxide administered to control hyperphosphataemia. Hyperaluminaemia may result from the use Bone aluminium and mineralisation mineralisation defect that occurred resulted from the accompanying hypophosphataemia and could be prevented by giving the animals a dietary supplement of phosphate. In their opinion, the symptoms of aluminum toxicity described by Berlyne et al. (1972) are non-specific.
We wished to reassess the possible toxicity of aluminium in animals with intact kidneys by administering aluminium parenterally to avoid hypophosphataemia and to see if histological osteomalacia developed when the bone aluminium was increased to a concentration similar to that found in the bones of our dialysis patients. Dialysis osteomalacia is a serious problem in Newcastle upon Tyne, and bone samples from some of our patients were among those with most aluminium in the previously reported data (Parsons et al., 1971) . The measurements were then made on bone ash by thermal neutron activation analysis without allowance for the activation of phosphorus to 28AI, though the omission did not significantly affect the results at the levels observed in the samples from Newcastle patients. In this paper we report (i) values for the aluminium content of bone from control subjects and from non-dialysed and dialysed patients with chronic renal failure, using an improved neutron activation analysis technique , and (ii) the effects of the long-term intraperitoneal administration to rats of aluminium chloride, with particular reference to bone mineralisation and increased bone aluminium.
Materials and methods

PATIENTS AND METHODS
Iliac bone was obtained at necropsy (32) or at biposy (2) from 34 patients with chronic renal failure. Details of these patients are given in Table 1 . +  8  122  29  60  M  15  47 mth  4   691  IV  I   -2  28  30  51  M  34  38 mth  4  255  II id  0  +  5  29  31  50  M  40  46 mth  4  236  I  0  -4  33  32  56  F  48  60 mth   4   1252  IV  2-5  -3  165  33  42  M  72  52 mth   4  1702  IV  0  -4  56  34  47  M 116  3 mth  4+  281  II  0  +  6  213 *See Gilmour (1947) The data for the eight control subjects are given in Table 2 . The mean whole bone aluminium is 5 7 ± I 0 ppm bone ash. Aluminium in compact and cancellous bone The amounts of aluminium in whole bone, cancellous bone, and cortical bone relating to three control subjects and 12 patients with renal disease are given in Table 5 Relation between bone aluminium and hyperparathyroidism The parathyroid glands were enlarged and hyperplastic in the renal patients, irrespective of treatment by haemodialysis or renal transplantation. Although dialysis may be associated with a reduction in the severity of histological osteitis fibrosa the parathyroids remain enlarged. Plotting the weight of parathyroid glands against the bone aluminium concentration reveals no relation in dialysed or nondialysed patients. There is no relation between the histological grade of severity of osteitis fibrosa and the bone aluminium content.
Relation between bone aluminium and osteomalacia
The cause of osteomalacia in non-dialysed patients Regarding the duration and severity of the osteomalacia and the bone aluminium, there is no significant relation between the thickness of the osteoid seams (as indicated by the maximum number of birefringent lamellae) and the bone aluminium (correlation coefficient r = 0-218, P > 0-10).
EXPERIMENTAL RAT DATA Experiment 1: 52 days' aluminium chloride injections
The test animals failed to gain weight at the normal rate after two to three weeks' injections of aluminium chloride (Fig. 4) but did not develop periorbital bleeding or conjunctival ulceration. There was a fibrinous chemical peritonitis with adhesions, including aluminium granulomata covering the bowel, spleen, and liver. Otherwise there was no histological abnormality of the liver, spleen, pancreas, kidney, heart, or lungs. The serum calcium, phosphorus, alkaline phosphatase, and urea were normal ( Table  7) . The alkaline phosphatase was of the intestinal type, which is normal in rats. The amount of aluminium in the whole femora of four rats treated with aluminium chloride was increased (range 90-124, mean 109 3 ppm of bone ash- Table 7 ) compared with that in six untreated rats (range 2-30, mean ± SE, 15A4 ± 4-7 ppm) (Tables 7 and 8) . Radiographs of the tibiae and femora revealed no widening or irregularity of the epiphyseal cartilaginous plates nor change in the width of the zone of metaphyseal spicules of bone and cartilage. Measurements made from radiographs of the tibiae showed that the diaphyseal lengths and the mid-diaphyseal cortical bone widths were unaffected by aluminium chloride treatment (controls: mean 38-0 mm and 0 9 mm, respectively, compared with 39-1 mm and 0 9 mm for test rats).
Undecalcified sections of tibiae confirmed that endochondral ossification was normal with the usual maturation of chondrocytes and mineralisation of cartilage matrix. Where new bone was being formed on the metaphyseal cartilaginous septa, on the inner aspect of the diaphyseal cortical bone, and in the trabeculae of the epiphysis and diaphysis, there was no excess of osteoid, the seams were normal in width, comprising one to two bright lamellae under crossed polaroids, and there was a normal calcification front. Thus, in spite of a marked increase in the bone aluminium, none of the test rats had any histological evidence of a mineralisation defect after 52 days' treatment with aluminium chloride.
Experiment 2
The test animals failed to gain weight normally, but in those animals in which aluminium chloride injections had been discontinued (rats 17 and 18 for 27 days; rats 13, 14, and 15 for 49 days) there was a subsequent increase in body weight. Four rats (7, 8, 9, 16 ) died during the experiment. None of the animals developed periorbital haemorrhages or conjunctival ulceration. General postmortem and The whole femur bone aluminium content was increased in the 16 rats given aluminium chloride (mean ± SE = 176 ± 8 2 ppm ash compared with 15 4 ± 4-7 ppm for six untreated rats). In 10 test animals where the marrow free diaphysis was also analysed there was a similar increase in aluminium (181-6 ± 9 0 ppm), confirming that the excess aluminium had accumulated in the bone tissue (Table 8) . Bone aluminium remained elevated in the five rats in which aluminium injections were discontinued up to 49 days. Radiographs of the tibiae and femora of the aluminium-injected rats showed no definite widening or irregularity of the epiphyseal cartilaginous plates. In rats 13, 14, and 15, which had received aluminium over a period of 63 days and then rested for 49 days, there was a radiodense band at the metaphysis equivalent to about twice the width of the normal radiolucent epiphyseal plate and 1 .5 mm away from it. In rats 19, 20, 21, and 22, after 85 days' aluminium the distinction between the radiolucent epiphyseal plate and the subjacent primary trabeculae zone was less well defined than normal. Rats 17 and 18, after 84 days' aluminium followed by a 27-day rest period, showed a normal radiolucent epiphyseal plate with a clearcut distinction between the zone of primary trabeculae, but this zone was hazy in appearance. Measurements of the tibial radiographs revealed no definite shortening of the bone. Thus, excluding the four rats which died, the mean length ± SE for 12 treated rats was 40 0 ± 0 3 mm compared with 39 7 + 0 7 mm for the four controls. The treated animals did show some thinning of the cortical bone, only one animal having as thick a cortex as the controls. The mean cortical width at the mid-diaphysis for 12 treated rats was 0 80 ± 0 03 mm compared with 1 0 + 0 4 mm for the controls.
Undecalcified sections of tibiae revealed an abnormality of bone mineralisation which varied in degree and distribution, depending upon the duration of aluminium treatment, and the various appearances will be described separately:
(a) 4 Control rats: None of the control rats had any evidence of a mineralisation defect of cartilage or bone. At the sites of bone formation the normal osteoid seams comprised one to two lamellae.
(b) Rats dying after 48 to 53 days' aluminium chloride injections (Nos 7, 8, and 9): The epiphyseal cartilaginous plates appeared normal in width and shape, and there was no abnormality of cartilage mineralisation. In rat 7, after 48 days' aluminium chloride there was no excess of osteoid, the seams comprised one to two lamellae, and the calcification front was not reduced. Rats 8 and 9, after 50 and 53 days' aluminium chloride, respectively, showed a slight excess of osteoid at the metaphysis, lining the internal aspect of the adjacent diaphyseal cortex, and focally on cancellous trabeculae of the epiphysis and diaphysis. In rat 8 the seams were normal in width with one to two lamellae, but in rat 9 some seams comprised four lamellae and lacked a calcification front, and the appearances suggested the onset of a mineralisation defect.
(c) Rats 19, 20, 21, and 22 (killed 85 days): There was minimal, if any, increase in width of the epiphyseal cartilaginous plates, which were regular in outline. The cartilage septa were mineralised but were covered by an excess of thick woven osteoid including some osteocytes over a length slightly greater than the depth of the epiphyseal plate (Fig. 5) . There was patchily distributed excess lamellar osteoid on diaphyseal and epiphyseal trabeculae with wide seams comprising five or six lamellae and with a reduction in the calcification front. Most osteoid was present in rat 20 but all five rats had osteomalacia. was also an excess of patchily distributed osteoid in the epiphyseal trabeculae and on the subperiosteal and endosteal aspects of the compact cortical bone of the diaphysis (Fig. 6) . At the metaphysis the endosteal osteoid seam most recently formed was H. A. Ellis, J. H. McCarthy, and J. Herrington normal in width and possessed a calcification front, but elsewhere in the wide seams the front was reduced. The wide osteoid seams comprised up to seven to 10 lamellae in rats 17 and 18, respectively. Both these animals thus showed features of persistent and worsening osteomalacia away from the zone of endochondral ossification at a time when endochondral ossification itself was normal.
Some of the main changes described in the affected rats are illustrated in Figs. 5 and 6 and are summarised diagrammatically in Fig. 7 .
Relation between bone aluminium and amount of aluminium injected Bone aluminium was related to the duration of the aluminium injection period and to the total dose of aluminium (Tables 7 and 8 ). There was retention of aluminium in bone for up to 49 days after the cessation of aluminium chloride injections.
Observation on bone linear growth rates in aluminiumtreated rats Measurements made of the length of abnormal osteoid on the cartilage septa and its distance from the epiphyseal plate in animals rested after aluminium treatment make it possible to estimate the approximate rate of linear growth of bone. Assuming the mineralisation defect was manifest at about 53 days, then to accumulate the measured mean length of 0.07 mm of osteoid alongside the septa at 63 days the rate was 0 007 mm/day. At 85 days the mean length of osteoid was 0.27 mm, a gain of 0.2 mm in 22 days, or a rate of 0 .009 mm per day. During the rest period, after 84 days' injection rats 2 and 5 had a mean length of 0 38 mm of osteoid 0-29 mm from the cartilage plate so that the band of osteoid on the cartilage septa had moved 8-67 mm in 27 days, that is, 0-025 mm per day. This last rate for rats after the cessation of aluminium is similar to the rate we found previously in normal rats (Ellis and Peart, 1971b) This patient also had severe osteomalacia relative to the degree of osteitis fibrosa and terminal symptoms reminiscent of those of dialysis encephalopathy.
Although hyperaluminaemia and increased bone aluminium may result from the use of oral aluminium hydroxide and absorption of aluminium may be increased by hyperparathyroidism (Mayor et al., 1977) It would be of interest to know the precise localisation of the aluminium in the bone to see if this is in accord with the hypothesis that the accumulated aluminium in the osteoid formed at the time of the aluminium injections prevents proper mineralisation of that osteoid. Unfortunately, we do not have any information concerning the exact site of the bone aluminium, since attempts to locate aluminium in undecalcified bone blocks from patients and rats by Stereoscan scanning electron microscopy or by histochemical means in sections have proved unsuccessful, presumably because of the low concentrations of aluminium involved. Since haemodialysis patients appear to continue accumu-lating aluminium in bone with increasing time on dialysis, and osteomalacia also becomes commoner and more osteoid is formed the longer the period of dialysis, it seems likely that some of the aluminium accumulates in the osteoid. There is no information available to indicate how the accumulated aluminium may inhibit normal mineralisation. It has been suggested that treatment with aluminium compounds interferes with phosphate metabolism. Most of the work reported has been based on animals given aluminium hydroxide or chloride by mouth, when the aluminium forms insoluble phosphates in the gastrointestinal tract, causing a negative balance in phosphorus. In such circumstances hypophosphataemia may cause rickets which can be prevented by supplementing the diet with phosphates (Thurston et al., 1972) . However, others (Ondreicka et al., 1966) have reported that when the effects on the absorption of phosphorus are eliminated, then feeding high doses of aluminium salts still affects phosphorylation mechanisms in the tissues. The absence of hypophosphataemia in our animals does not exclude the possibility that aluminium chloride interferes with phosphate metabolism in bone tissues.
The present experiments have revealed a hitherto undescribed and unusual form of mineralisation defect, histological osteomalacia developing in rats after the long-term intraperitoneal administration of aluminium chloride and unaccompanied by hypophosphataemia. The experiments do not conclusively prove that aluminium toxicity is the direct cause of the osteomalacia. We are currently carrying out further experiments with this model to ascertain whether or not the development of osteomalacia in aluminium chloride injected rats can be prevented or treated by supplements of parenteral vitamin D. As a further precaution we are also studying the mineralisation status of bone in a pair weight gain control to each of the animals treated with aluminium chloride.
If it is subsequently proved that aluminium is indeed directly interfering with bone mineralisation then the present experimental results would have some important implications for haemodialysis patients. In particular, the retention of aluminium in the bones of rats after the cessation of aluminium treatment, even in the presence of intact kidneys, suggests that once the patients' bones are loaded with aluminium elimination might be difficult and the aluminium could exert a detrimental effect on mineralisation long after exposure to aluminium had ceased. Thus osteomalacia might persist after substitution of a dialysate prepared from a water supply with a lower concentration of aluminium or after renal transplantation.
